Preclinical drug development usually takes several years from the identification of a new chemical entity (NCE) to advance to clinical testing. Most of these pharmacokinetics (PK)/pharmacodynamics (PD) and formulation evaluations are required for Investigational New Drug (IND) applications. Two aspects are generally involved for an NCE at this stage: 1) in vitro PK characterizations (physiochemical properties, metabolism, stability, and cellular and gastrointestinal permeability); and 2) in vivo PK and PD evaluations in animal models. In addition, most NCEs are either unstable or unsuitable for conventional routes of drug administration. Thus, developing an optimal dosage formulation is critical for further NCE candidate development.  Gulf Coast Consortia (GCC) Center for Comprehensive PK/PD & Formulation (CCPF), was established in 2018 with funding support from Cancer Prevention & Research Institute of Texas (CPRIT) (insert CPRIT website https://www.cprit.state.tx.us/). It received $5.2 millions from CPRIT for 2018-2024 and an additional $2 millions for 2024-2029. GCC-CCPF is a state-of-the-art drug development core facility with experienced faculty from Texas Southern University College of Pharmacy and Health Science (TSU COPHS) (http://www.tsu.edu/academics/colleges-and-schools/college-of-pharmacy-and-health-sciences/index.html), University of Houston College of Pharmacy (UHCOP) (http://www.uh.edu/pharmacy/index), and the GCC for Quantitative Biomedical Science (https://www.gulfcoastconsortia.org/) . Our primary focus is on preclinical drug development to facilitate rapid advancement of novel cancer drug candidates to clinical trials. We are proud to provide critically needed PK/PD and formulation services to streamline the drug development of potential anti-cancer drug candidates identified in existing drug discovery cores, individual labs, and small companies throughout Texas. In the past eight (8) years, we have provided over 300 project services for various Texas investigators and supported their grant applications, IND filings, and product commercialization.